HESBURGH LECTURE SERIES 2013 Program - Alumni Association ...
HESBURGH LECTURE SERIES 2013 Program - Alumni Association ...
HESBURGH LECTURE SERIES 2013 Program - Alumni Association ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Mayland Chang, Ph.D.<br />
Research Professor; Department of Chemistry and Biochemistry;<br />
Director, Notre Dame Project Development Team<br />
Biography<br />
Mayland Chang, research professor in the Department of Chemistry and Biochemistry, brings<br />
22 years of experience in drug discovery and development, and clinical trials management.<br />
She has characterized the absorption, distribution, metabolism, and excretion (ADME)<br />
properties of numerous drug candidates in the areas of infectious, CNS, and metabolic<br />
Categories<br />
diseases, including delavirdine (a reverse transcriptase inhibitor, Rescriptor Tablets),<br />
atevirdine (a reverse transcriptase inhibitor), sonepiprazole (a D4-antagonist), linomide (an Notre Dame, Science<br />
anti-angiogenic), PNU-96391 (a D2-antagonist), and PNU-183792 (a non-nucleoside inhibitor<br />
of human cytomegalovirus). Chang also prepared the Rescriptor Tablets NDA and various<br />
IND applications, Investigator’s Brochures, product development plans, candidate drug evaluations, and acquisition of candidate<br />
drugs, as well as the ADME package for delavirdine in defense of the marketing approval with the U.S. FDA and the ADME<br />
section of delavirdine’s package insert.<br />
Before joining the University of Notre Dame, Chang was chief operating officer of University Research Network, Inc., where she<br />
established an academic research organization for Wayne State University School of Medicine that facilitated clinical research and<br />
provided clinical development services to the pharmaceutical and biotechnology industries. Previously, she was senior scientist<br />
with Pharmacia Corporation (Pfizer, Inc. as of 2003), and senior chemist at Dow Chemical Company. During her industrial career,<br />
Chang has seen three of her projects brought to commercialization (Rescriptor Tablets for the treatment of HIV, Broadstrike<br />
herbicide, and Tracer insecticide). More recently, she has studied the metabolism and pharmacokinetics of SB-3CT, a selective<br />
gelatinase inhibitor that shows efficacy in animal models of stroke and cancer metastasis. She has designed and evaluated watersoluble<br />
gelantinase inhibitors that show great promise in the treatment of neurological diseases.<br />
Chang holds bachelor’s degrees in biology and chemistry from the University of Southern Carolina, a Ph.D. in chemistry from the<br />
University of Chicago, and has completed a NIH postdoctoral fellowship at Columbia University. Her research interests center on<br />
defining and optimizing the ADME properties of pharmacologically active compounds and designing prodrugs with improved<br />
pharmaceutical and pharmacokinetic properties.<br />
Lecture<br />
Win Just One for the Gipper: Advances Toward Treatment of Traumatic Brain Injury<br />
Concussions are a prominent feature of sports, producing a cascade of neurological events, resulting in reduced blood flow to<br />
the brain, neuronal cell injury, and death. Presently, there is no treatment to rescue brain cells after each concussion. Notre Dame<br />
technology addresses this unmet medical need that has the potential for a first-in-kind treatment for TBI.<br />
20 The Hesburgh Lecture Series, <strong>2013</strong> <strong>Program</strong>